Sutro Biopharma, Inc. (FRA:S090)

Germany flag Germany · Delayed Price · Currency is EUR
6.78
-0.41 (-5.70%)
At close: Dec 2, 2025
-72.88%
Market Cap 63.38M
Revenue (ttm) 90.04M
Net Income (ttm) -184.75M
Shares Out n/a
EPS (ttm) -22.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume n/a
Open 6.56
Previous Close 7.19
Day's Range 6.56 - 6.78
52-Week Range 4.66 - 27.20
Beta n/a
RSI 40.01
Earnings Date Mar 27, 2026

About Sutro Biopharma

Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in P... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2003
Employees 310
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol S090
Full Company Profile

Financial Performance

In 2024, Sutro Biopharma's revenue was $62.04 million, a decrease of -59.64% compared to the previous year's $153.73 million. Losses were -$227.46 million, 113.0% more than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.